Our trial of ondansetron as a treatment for hallucinations in Parkinson's is restarting Date 22 November 2024
Parkinson’s ambassador David Jensen joins Jazz FM Date 18 February 2021 The broadcasting legend will front a new 6-part jazz series, which will also highlight the work of Parkinson’s UK.
Further clues about alpha-synuclein Date 11 February 2021 New research has advanced our understanding of a protein called alpha-synuclein, which is believed to play a central role in damaging brain cells in Parkinson’s.
Shan Nicholas joins the team as Interim Chief Executive Date 20 January 2021 As Steve Ford prepares to step down, Shān brings extensive leadership experience from across the charity sector to Parkinson’s UK.
Vision tests predict cognitive decline linked to Parkinson's Date 19 January 2021 Scientists in the UK have uncovered evidence that simple vision tests can predict who will develop Parkinson's dementia. And the evidence shows that a loss of wiring in the brain may be the cause.
New guidance for lab-based researchers on patient and public involvement Date 8 January 2021 We’ve partnered with Alzheimer’s Society and University College London Hospitals (UCLH) Biomedical Research Centre. Together, we’ve developed a new resource to help lab-based researchers with patient and public involvement (PPI).
What we achieved in 2020, together Date 15 December 2020 Parkinson's didn't stop for coronavirus, and neither did we. Here are the three things we’re most proud of this year, and how you can get involved in 2021.
Volunteer Awards 2020: congratulations to our award winners! Date 8 December 2020 Our 2020 volunteer award winners have been announced
Parkinson's medication fails to control symptoms for nearly 75% of people Date 2 December 2020 Our recent survey has found that nearly three quarters (74%) of people on Parkinson's medication experience 'wearing off', when symptoms including pain, stiffness and tremors become worse between doses.
New trial to drive forward promising treatment for dyskinesia Date 22 November 2020 Parkinson’s UK is joining forces with US charity The Michael J. Fox Foundation and biopharma company Neurolixis to fund a £1.5m clinical trial of an exciting new drug to combat dyskinesia in people with Parkinson’s.
Caption Steve smiling Steve Ford stepping down as CEO Date 12 November 2020 After 15 years leading the charity, Steve Ford is saying a fond farewell to Parkinson's UK at the end of January 2021. He'll then start his search for a new challenge.
